About Summit Therapeutics
Summit Therapeutics (NASDAQ:SMMT) is a biopharmaceutical company deeply involved in the discovery, development, and commercialization of novel medicines for diseases lacking effective treatments. Concentrating particularly on infectious diseases and precision medicines for specific patient populations, Summit is at the forefront of tackling healthcare challenges with innovative approaches. Its projects often focus on new therapies for antibiotic-resistant bacterial infections and rare diseases, reflecting its commitment to addressing critical unmet medical needs. Through rigorous research and clinical programs, Summit Therapeutics aims to bring groundbreaking treatments to market, thereby improving patient outcomes and quality of life. The firm's objectives are centered around advancing its pipeline to commercial success while adhering to the highest scientific and ethical standards.
Snapshot
Operations
Products and/or services of Summit Therapeutics
- Ridinilazole, a novel antibiotic for Clostridioides difficile infection (CDI), aimed at significantly reducing CDI recurrence rates while being sparing of the gut microbiome.
- Ezutromid, a utrophin modulator designed for the treatment of Duchenne Muscular Dystrophy (DMD), aiming to maintain muscle function and slow disease progression.
- SMC021, an oral formulation of salmon calcitonin for the treatment of osteoarthritis, intended to reduce pain and improve joint function.
- Discuva Platform, a proprietary technology for the rapid identification and development of novel antibiotics, addressing the global crisis of antimicrobial resistance.
- Biobetter Antibodies, advanced antibody therapies designed to improve upon existing treatments for autoimmune diseases and cancers with enhanced efficacy and safety profiles.
- Precision Medicine Program, leveraging genetic insights and advanced analytics to develop targeted therapies for rare diseases and specific patient populations.
Summit Therapeutics executive team
- Mr. Robert W. DugganCo-CEO & Executive Chairman
- Dr. Mahkam Zanganeh D.D.S., M.B.A.Co-CEO, President & Director
- Mr. Manmeet Singh Soni CPACOO, CFO & Director
- Prof. Kay Elizabeth Davies DBE, FRS CBECo-Founder, Chairman of Scientific Advisory Board and Scientific Advisor
- Mr. Bhaskar AnandChief Accounting Officer
- Mr. Nathan LiaBraatenSenior Director of Investor Relations
- Mr. Dave GancarzChief Business & Strategy Officer
- Dr. Fong ClowChief Biometrics Officer
- Dr. Urte Gayko Ph.D.Chief Regulatory, Quality & Pharmacovigilance Officer
- Dr. Allen S. Yang M.D., Ph.D.Head of R&D Strategy